| Net income | |
| Depreciation, depletion and amortization | |
| Amortization of debt issuance costs | 0 |
| Terminated transaction costs | |
| Deferred income tax expense | |
| Unrealized losses (gains) from the change in market value of open derivative contracts | |
| Stock-based compensation | 0 |
| Loss on sale of other assets | 0 |
| Accretion expense- asset retirement obligation | 0 |
| Accounts receivable | |
| Inventory | |
| Other current assets | |
| Accounts payable | |
| Other accrued liabilities | |
| Net cash provided by operating activities | -2.53M |
| Capital expenditures | 0 |
| Proceeds from sale of other property and equipment | |
| Other assets | |
| Net cash used in investing activities | 0 |
| Proceeds from revolving credit facility borrowings | |
| Payments on revolving credit facility | 0 |
| Proceeds from exercise of stock options | |
| Deferred financing costs | |
| Deferred financing costs related to terminated transaction costs | |
| Payments on other debt | |
| Purchase and cancellation of treasury stock | |
| Cash dividends paid on Series A Convertible Redeemable Preferred Stock | -1.73M |
| Net cash used in financing activities | -1.73M |
| Effect of exchange rate changes on cash | |
| Increase (decrease) in cash and cash equivalents | -4.27M |
| Cash and cash equivalents at beginning of period | 22.89M |
| Cash and cash equivalents at end of period | 18.63M |
| Accrued capital expenditures | |